Vor Biopharma (VOR) Liabilities and Shareholders Equity (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $506.7 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $506.7 million, up 363.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 165.31% YoY), and the FY2025 annual result was $464.1 million, up 224.81% from the prior year.
• Liabilities and Shareholders Equity advanced to $506.7 million in Q1 2026 per VOR's latest filing, from $464.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $506.7 million in Q1 2026 and troughed at $109.3 million in Q1 2025.
• A 5-year average of $232.0 million and a median of $206.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity slumped 47.99% in 2024, then soared 363.58% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $299.4 million in 2022, then slumped by 33.82% to $198.1 million in 2023, then fell by 27.88% to $142.9 million in 2024, then soared by 224.81% to $464.1 million in 2025, then climbed by 9.18% to $506.7 million in 2026.
• Business Quant data shows VOR's Liabilities and Shareholders Equity at $506.7 million in Q1 2026, $464.1 million in Q4 2025, and $176.2 million in Q3 2025.